Ritonavir

Other Medications

Description

Ritonavir is a medication currently being studied in clinical trials, often in combination with other drugs, for certain types of advanced or metastatic cancers. In the context of colorectal cancer, it is being investigated in trials, sometimes for patients whose tumors have specific characteristics like HER2 expression or mutation. Ritonavir is primarily known as an antiviral drug used to treat HIV, but researchers are exploring its potential role in cancer treatment, possibly due to its effects on drug metabolism or other cellular processes. The specific role and effectiveness of ritonavir in colorectal cancer are still under investigation in ongoing clinical trials.

Mechanism of Action

Ritonavir is primarily known as a protease inhibitor used to treat HIV. In the context of cancer research, its mechanism is being investigated. It is often used in clinical trials as a pharmacokinetic enhancer, meaning it can affect how other drugs are processed by the body, potentially increasing their levels or duration of action. In some trials, it is being studied in combination with other cancer therapies to see if it can improve their effectiveness or overcome resistance. The specific way ritonavir might directly affect cancer cells or the tumor microenvironment is still being researched.

Side Effects

Ritonavir is an established medication with known side effects when used for HIV. These can include nausea Vomiting Diarrhea Fatigue And changes in blood sugar or fat levels. When used in cancer clinical trials Side effects are carefully monitored. Common side effects observed in trials involving ritonavir (often in combination with other agents) can include fatigue Nausea Diarrhea And changes in liver function tests. Because ritonavir is being studied in new combinations and contexts for cancer The full range of potential side effects and their frequency are still being evaluated in ongoing clinical trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05150691 Phase 1
Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
United States, Australia, China, Puerto Rico, South Korea, Taiwan